Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) Stock Competitors & Peer Comparison
See HROWL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HROWL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| RPRX | $60.85 | -1.73% | 27B | 11.59 | $5.25 | +1.52% |
| CORT | $113.88 | -2.61% | 12.3B | 325.37 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| KNSA | $78.08 | -0.76% | 6.1B | 88.67 | $0.90 | N/A |
| LQDA | $67.69 | -3.22% | 6B | 483.50 | $0.14 | N/A |
| PBH | $52.47 | +2.46% | 2.5B | 11.87 | $4.42 | N/A |
| LTGO | $24.23 | -3.08% | 1.5B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| HELP | $12.18 | -8.01% | 755M | -2.92 | -$4.16 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
HROWL vs RPRX Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, RPRX has a market cap of 27B. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while RPRX trades at $60.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 11.59. In terms of profitability, HROWL's ROE is -1.04%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, HROWL is less volatile compared to RPRX. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
HROWL vs CORT Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while CORT trades at $113.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 325.37. In terms of profitability, HROWL's ROE is -1.04%, compared to CORT's ROE of +0.08%. Regarding short-term risk, HROWL is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
HROWL vs WBA Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas WBA's P/E ratio is -1.64. In terms of profitability, HROWL's ROE is -1.04%, compared to WBA's ROE of -0.42%. Regarding short-term risk, HROWL is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for HROWL.Check WBA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
HROWL vs KNSA Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, KNSA has a market cap of 6.1B. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while KNSA trades at $78.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 88.67. In terms of profitability, HROWL's ROE is -1.04%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, HROWL is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
HROWL vs LQDA Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, LQDA has a market cap of 6B. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while LQDA trades at $67.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is 483.50. In terms of profitability, HROWL's ROE is -1.04%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, HROWL is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
HROWL vs PBH Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, PBH has a market cap of 2.5B. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while PBH trades at $52.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas PBH's P/E ratio is 11.87. In terms of profitability, HROWL's ROE is -1.04%, compared to PBH's ROE of +0.09%. Regarding short-term risk, HROWL is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check PBH's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
HROWL vs LTGO Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, LTGO has a market cap of 1.5B. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while LTGO trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas LTGO's P/E ratio is N/A. In terms of profitability, HROWL's ROE is -1.04%, compared to LTGO's ROE of N/A. Regarding short-term risk, HROWL is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check LTGO's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
HROWL vs HROWM Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas HROWM's P/E ratio is N/A. In terms of profitability, HROWL's ROE is -1.04%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, HROWL is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for HROWL.Check HROWM's competition here
Cybin Inc. Common Stock (NASDAQ: HELP)
HROWL vs HELP Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, HELP has a market cap of 755M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while HELP trades at $12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas HELP's P/E ratio is -2.92. In terms of profitability, HROWL's ROE is -1.04%, compared to HELP's ROE of -0.71%. Regarding short-term risk, HROWL is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
HROWL vs SVA Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas SVA's P/E ratio is -5.68. In terms of profitability, HROWL's ROE is -1.04%, compared to SVA's ROE of -0.01%. Regarding short-term risk, HROWL is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for HROWL.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
HROWL vs CUVL Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, CUVL has a market cap of 310.6M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while CUVL trades at $6.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas CUVL's P/E ratio is N/A. In terms of profitability, HROWL's ROE is -1.04%, compared to CUVL's ROE of N/A. Regarding short-term risk, HROWL is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check CUVL's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
HROWL vs CELG-RI Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, CELG-RI has a market cap of 244.7M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, HROWL's ROE is -1.04%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, HROWL is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
HROWL vs HITI Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, HITI has a market cap of 220.6M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while HITI trades at $2.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas HITI's P/E ratio is -7.36. In terms of profitability, HROWL's ROE is -1.04%, compared to HITI's ROE of -0.43%. Regarding short-term risk, HROWL is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check HITI's competition here
Atlantic International Corp. (NASDAQ: ATLN)
HROWL vs ATLN Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas ATLN's P/E ratio is -0.68. In terms of profitability, HROWL's ROE is -1.04%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, HROWL is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check ATLN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
HROWL vs CTOR Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, CTOR has a market cap of 72.1M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while CTOR trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas CTOR's P/E ratio is -1.65. In terms of profitability, HROWL's ROE is -1.04%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, HROWL is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check CTOR's competition here
Stablecoin Development Corp. (AMEX: SDEV)
HROWL vs SDEV Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, SDEV has a market cap of 47.8M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while SDEV trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas SDEV's P/E ratio is -0.17. In terms of profitability, HROWL's ROE is -1.04%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, HROWL is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check SDEV's competition here
Rite Aid Corporation (NYSE: RAD)
HROWL vs RAD Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas RAD's P/E ratio is -0.05. In terms of profitability, HROWL's ROE is -1.04%, compared to RAD's ROE of +2.76%. Regarding short-term risk, HROWL is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check RAD's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
HROWL vs NSRX Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, NSRX has a market cap of 34.9M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while NSRX trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas NSRX's P/E ratio is -5.62. In terms of profitability, HROWL's ROE is -1.04%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, HROWL is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check NSRX's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
HROWL vs GLTO Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas GLTO's P/E ratio is -1.78. In terms of profitability, HROWL's ROE is -1.04%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, HROWL is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check GLTO's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
HROWL vs SCYX Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, SCYX has a market cap of 34M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while SCYX trades at $5.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -1.58. In terms of profitability, HROWL's ROE is -1.04%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, HROWL is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check SCYX's competition here
Cerenome, Inc. (NASDAQ: CNSY)
HROWL vs CNSY Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, CNSY has a market cap of 21M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while CNSY trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas CNSY's P/E ratio is -0.42. In terms of profitability, HROWL's ROE is -1.04%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, HROWL is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check CNSY's competition here
Biofrontera Inc. (NASDAQ: BFRI)
HROWL vs BFRI Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, BFRI has a market cap of 20.4M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while BFRI trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas BFRI's P/E ratio is -2.89. In terms of profitability, HROWL's ROE is -1.04%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, HROWL is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check BFRI's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
HROWL vs SCNX Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, SCNX has a market cap of 16M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while SCNX trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas SCNX's P/E ratio is -0.16. In terms of profitability, HROWL's ROE is -1.04%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, HROWL is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check SCNX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
HROWL vs BFRIW Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, BFRIW has a market cap of 14.2M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, HROWL's ROE is -1.04%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, HROWL is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
HROWL vs COSM Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, COSM has a market cap of 12.2M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while COSM trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas COSM's P/E ratio is -0.30. In terms of profitability, HROWL's ROE is -1.04%, compared to COSM's ROE of -1.19%. Regarding short-term risk, HROWL is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check COSM's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
HROWL vs CJJD Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas CJJD's P/E ratio is -0.46. In terms of profitability, HROWL's ROE is -1.04%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, HROWL is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
HROWL vs SSY Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas SSY's P/E ratio is -2.86. In terms of profitability, HROWL's ROE is -1.04%, compared to SSY's ROE of -0.09%. Regarding short-term risk, HROWL is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
HROWL vs POM Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, POM has a market cap of 6.4M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while POM trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas POM's P/E ratio is -0.19. In terms of profitability, HROWL's ROE is -1.04%, compared to POM's ROE of +0.16%. Regarding short-term risk, HROWL is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
HROWL vs BGMS Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, BGMS has a market cap of 4.9M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while BGMS trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas BGMS's P/E ratio is -0.25. In terms of profitability, HROWL's ROE is -1.04%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, HROWL is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check BGMS's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
HROWL vs PAVS Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, PAVS has a market cap of 4.1M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while PAVS trades at $4.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas PAVS's P/E ratio is -0.05. In terms of profitability, HROWL's ROE is -1.04%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, HROWL is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
HROWL vs MDVL Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas MDVL's P/E ratio is -0.05. In terms of profitability, HROWL's ROE is -1.04%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, HROWL is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
HROWL vs ATNFW Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas ATNFW's P/E ratio is N/A. In terms of profitability, HROWL's ROE is -1.04%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, HROWL is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
HROWL vs BGMSP Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, HROWL's ROE is -1.04%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, HROWL is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
HROWL vs AZNH Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas AZNH's P/E ratio is 38.35. In terms of profitability, HROWL's ROE is -1.04%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, HROWL is less volatile compared to AZNH. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
HROWL vs LFLYW Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, HROWL's ROE is -1.04%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, HROWL is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for HROWL.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
HROWL vs PRPH Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, PRPH has a market cap of 295.7K. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while PRPH trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas PRPH's P/E ratio is -0.01. In terms of profitability, HROWL's ROE is -1.04%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, HROWL is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check PRPH's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
HROWL vs CPD Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, CPD has a market cap of 0. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas CPD's P/E ratio is N/A. In terms of profitability, HROWL's ROE is -1.04%, compared to CPD's ROE of N/A. Regarding short-term risk, HROWL is less volatile compared to CPD. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check CPD's competition here
POZEN Inc. (NASDAQ: POZN)
HROWL vs POZN Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, POZN has a market cap of 0. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas POZN's P/E ratio is N/A. In terms of profitability, HROWL's ROE is -1.04%, compared to POZN's ROE of +0.61%. Regarding short-term risk, HROWL is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check POZN's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
HROWL vs ESRX Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas ESRX's P/E ratio is 10.69. In terms of profitability, HROWL's ROE is -1.04%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, HROWL is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for HROWL.Check ESRX's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
HROWL vs OREX Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, OREX has a market cap of 0. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas OREX's P/E ratio is -0.14. In terms of profitability, HROWL's ROE is -1.04%, compared to OREX's ROE of -0.54%. Regarding short-term risk, HROWL is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check OREX's competition here
Shire plc (NASDAQ: SHPG)
HROWL vs SHPG Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas SHPG's P/E ratio is 11.35. In terms of profitability, HROWL's ROE is -1.04%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, HROWL is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for HROWL.Check SHPG's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
HROWL vs IPXL Comparison September 2026
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWL stands at 1.4B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, HROWL is priced at $25.61 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWL currently has a P/E ratio of N/A, whereas IPXL's P/E ratio is -10.11. In terms of profitability, HROWL's ROE is -1.04%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, HROWL is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for HROWL.Check IPXL's competition here